Description
Peficitinib (ASP-015K, JNJ-54781532) is a potent JAK inhibitor with IC50s of 3.9 and 0.7nM for JAK1 and JAK3 respectively; inhibits IL-2-dependent T cell proliferation in vitro and STAT5 phosphorylation in vitro and ex vivo; dose-dependently suppresses bone destruction and paw swelling in an adjuvant-induced arthritis model in rats; orally bioactive. Rheumatoid Arthritis Phase 3 Clinical